Jul. 30 at 10:08 AM
$NVVE At the beginning of July, they were focused on closing the deal with Omnia (the
$150 million Series B funding round was legally ready). But it took longer than expected, and they neglected their non-compliance issues with the Nasdaq, thinking they could wait. When they saw their intransigence, their only plan B was to urgently terminate the warrant agreement to regain equity by diluting the position and publish the Q10 report to be compliant. This happened on July 15th, and from the 16th onwards, the bloodbath began. Now, most of the toxic rights have been exercised, and the ELOC has been effectively terminated by delisting. All points of non-compliance have been resolved, and they have a good chance of quickly being reinstated on the Nasdaq if they have appealed as they have stated. Given the CTB and availability share and nano free float, What would happen if the Nasdaq re-listing was announced at the same time as the delivery of Omnia's milestones on illiquid OTC stock?i
